Novo Will Limit Wegovy’s China Launch to Avoid Global Disruption
- Danish drugmaker will face a delicate balancing act in China
- Local authorities cleared obesity blockbuster Wegovy this week
This article is for subscribers only.
Novo Nordisk A/S will restrict initial sales of its blockbuster obesity treatment Wegovy in China, as the drugmaker grapples with how to control access to the medicine for the world’s biggest population of obese people.
Novo will face a delicate balancing act in China as it attempts to meet pent-up demand and take advantage of what may only be a brief head start on arch-rival Eli Lilly & Co.